Specifically, two recurrent mutations have been reported for IDH2—IDH2R140 and IDH2R172, the latter being suggested as a diagnostic biomarker for the molecular subclassification of AML patients [20]. This evidence concerns the gene IDH2 and acute myeloid leukemia.